Prognostic markers for melanoma, particularly for stage II disease, are needed for the risk‐benefit evaluation of future adjuvant therapies. The mainly nuclear RNA‐binding protein human antigen R (HuR) regulates the protein expression of thousands of mRNAs, its own heterogeneous expression could therefore reflect tumor heterogeneity and plasticity. Here, we evaluate its quantification in primary melanoma as a marker of metastatic outcome.